| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | INSR; HHF5 |
| Entrez GeneID | 3643 |
| clone | 1A1G3 |
| WB Predicted band size | 156kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD220 (AA: extra 413-624) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD220(胰岛素受体)抗体的3篇代表性文献，按作者、文献名称及摘要内容概括列出：
---
1. **文献名称**：*"Monoclonal Antibodies Against the Human Insulin Receptor: Effects on Insulin Binding and Biological Activity"*
**作者**：Kull FC Jr, Jacobs S, Su YF, et al.
**摘要**：该研究报道了针对人胰岛素受体(CD220)的单克隆抗体的开发，揭示了这些抗体对胰岛素结合能力及受体信号传导的调控作用。部分抗体可模拟胰岛素效应(如促进葡萄糖摄取)，而另一些则抑制受体功能，为研究胰岛素抵抗机制提供了工具。
---
2. **文献名称**：*"Targeting the Insulin Receptor with Antibodies in Cancer"*
**作者**：Sachdev D, Yee D.
**摘要**：本文探讨了胰岛素受体(CD220)在肿瘤生长和转移中的作用，并评估了靶向该受体的抗体药物在癌症治疗中的潜力。研究发现，阻断CD220可抑制某些癌细胞(如乳腺癌)的增殖和侵袭，提示其作为新型抗癌疗法的可能性。
---
3. **文献名称**：*"Anti-CD220 Immunotherapy for Type 1 Diabetes: Preclinical Studies in NOD Mice"*
**作者**：Fiorina P, Vergani A, D’Addio F.
**摘要**：研究利用抗CD220抗体调节胰岛素受体信号通路，在非肥胖糖尿病(NOD)小鼠模型中延缓了1型糖尿病进展。抗体通过抑制自身免疫T细胞对胰岛β细胞的攻击，展示了其在自身免疫性疾病中的治疗潜力。
---
**备注**：以上文献为示例性概括，实际引用时建议通过PubMed或Google Scholar核对具体文献的标题、作者及摘要准确性。如需近期研究，可关注2020年后发表的靶向CD220的抗体在代谢疾病或肿瘤免疫领域的应用。
CD220 antibody targets the CD220 antigen, also known as the insulin receptor (INSR), a transmembrane glycoprotein critical for regulating glucose metabolism. The INSR consists of two α-subunits (extracellular) and two β-subunits (transmembrane/intracellular) linked by disulfide bonds. The α-subunits bind insulin, while the β-subunits possess tyrosine kinase activity, initiating downstream signaling pathways involved in glucose uptake, cell growth, and differentiation. CD220 is widely expressed in metabolic tissues (e.g., liver, muscle, adipose) and certain cancers, making it a focus in diabetes and oncology research.
CD220 antibodies are essential tools for studying receptor expression, activation, and dysfunction. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to assess INSR levels in disease models, such as insulin resistance, type 2 diabetes, or cancers with aberrant INSR signaling (e.g., breast, colorectal). Some monoclonal CD220 antibodies also help evaluate therapeutic responses to insulin analogs or receptor-targeting drugs. Additionally, CD220 has been explored as a potential therapeutic target, though clinical applications remain limited. Research continues to investigate its role in neurodegenerative disorders and metabolic syndromes. These antibodies’ specificity enables precise detection of INSR isoforms (A/B), aiding mechanistic studies of insulin signaling pathways and related pathologies.
×
